ASSESSMENT OF REAL-WORLD TREATMENT PATTERNS AND SURVIVAL OUTCOMES OF SMALL CELL LUNG CANCER PATIENTS IN ENGLAND UTILISING THE ENGLISH CANCER REGISTRY DATA
Author(s)
Tijana Stanic, MSc1, Ilana Gibbons, MSc1, Stephen Puntis, DPhil1, Tahira Akram, MD1, Kieran Brooks, MSc2, Nikolay Trankov, MSc2.
1Amgen Ltd., Cambridge, United Kingdom, 2IQVIA, London, United Kingdom.
1Amgen Ltd., Cambridge, United Kingdom, 2IQVIA, London, United Kingdom.
OBJECTIVES: This study evaluated real-world outcomes and treatment pathways in patients with extensive-stage small cell lung cancer (ES-SCLC) who received systemic anti-cancer therapy (SACT) in England. This included assessment of patient demographics and clinical characteristics; treatment patterns, regimen distributions across lines of therapy (LoT); key clinical outcomes - overall survival (OS), time to treatment discontinuation (TTD), and time to next treatment or death (TTNTD); healthcare resource utilisation (HCRU); and adverse events (AEs).
METHODS: A retrospective longitudinal cohort study of adults with incident ES-SCLC diagnosed between January 2013 and December 2023 who received ≥1 SACT was conducted using the English Cancer Registry (ECR) database, with follow-up to May 2025. Time-to-event outcomes (OS, TTD, TTNTD) were estimated using Kaplan-Meier methods, with censoring at loss to follow-up or end of study. Descriptive analyses summarised patient characteristics, treatment patterns, HCRU (per-patient-per-month), and AE incidence. Pre-specified subgroup stratifications included LoT, ECOG status, platinum sensitivity, and treatment regimens.
RESULTS: The final cohort included 18,275 patients; mean age at diagnosis was 67 years and 50.8% were male. Across all LoTs, the predominant treatment received was platinum-based chemotherapy. Most patients (92.3%) received platinum-based chemotherapy and etoposide at first-line (1L). Only 22.8% and 4.6% received second-line (2L) and third-line (3L) treatment, respectively. Median OS declined across LoTs (approximately 8.1, 5.6, and 4.9 months at 1L, 2L, and 3L) and was similar across subgroups. TTD and TTNTD were short, indicating rapid disease progression. Over 50% of patients experienced ≥1 AE, most commonly pneumotitis/pneumonia, agranulocytosis, anaemia/pallor, renal failure. HCRU was substantial, with high inpatient and outpatient use.
CONCLUSIONS: Real-world outcomes for ES-SCLC in England remain poor, with limited progression to later LoTs, short survival, and high clinical burden. Outcomes are consistently unfavourable across subgroups, highlighting a persistent unmet need for more effective and durable treatment options in this population.
METHODS: A retrospective longitudinal cohort study of adults with incident ES-SCLC diagnosed between January 2013 and December 2023 who received ≥1 SACT was conducted using the English Cancer Registry (ECR) database, with follow-up to May 2025. Time-to-event outcomes (OS, TTD, TTNTD) were estimated using Kaplan-Meier methods, with censoring at loss to follow-up or end of study. Descriptive analyses summarised patient characteristics, treatment patterns, HCRU (per-patient-per-month), and AE incidence. Pre-specified subgroup stratifications included LoT, ECOG status, platinum sensitivity, and treatment regimens.
RESULTS: The final cohort included 18,275 patients; mean age at diagnosis was 67 years and 50.8% were male. Across all LoTs, the predominant treatment received was platinum-based chemotherapy. Most patients (92.3%) received platinum-based chemotherapy and etoposide at first-line (1L). Only 22.8% and 4.6% received second-line (2L) and third-line (3L) treatment, respectively. Median OS declined across LoTs (approximately 8.1, 5.6, and 4.9 months at 1L, 2L, and 3L) and was similar across subgroups. TTD and TTNTD were short, indicating rapid disease progression. Over 50% of patients experienced ≥1 AE, most commonly pneumotitis/pneumonia, agranulocytosis, anaemia/pallor, renal failure. HCRU was substantial, with high inpatient and outpatient use.
CONCLUSIONS: Real-world outcomes for ES-SCLC in England remain poor, with limited progression to later LoTs, short survival, and high clinical burden. Outcomes are consistently unfavourable across subgroups, highlighting a persistent unmet need for more effective and durable treatment options in this population.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
RWD175
Topic
Clinical Outcomes, Patient-Centered Research, Real World Data & Information Systems
Topic Subcategory
Reproducibility & Replicability
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Oncology